Stefanik, M.; Ezebuo, F.C.; Haviernik, J.; Uzochukwu, I.C.; Fojtikova, M.; Salat, J.; Eyer, L.; Ruzek, D.
FDA Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses In Vitro. Proceedings 2020, 50, 6.
https://doi.org/10.3390/proceedings2020050006
AMA Style
Stefanik M, Ezebuo FC, Haviernik J, Uzochukwu IC, Fojtikova M, Salat J, Eyer L, Ruzek D.
FDA Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses In Vitro. Proceedings. 2020; 50(1):6.
https://doi.org/10.3390/proceedings2020050006
Chicago/Turabian Style
Stefanik, Michal, Fortunatus C Ezebuo, Jan Haviernik, Ikemefuna C. Uzochukwu, Martina Fojtikova, Jiri Salat, Ludek Eyer, and Daniel Ruzek.
2020. "FDA Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses In Vitro" Proceedings 50, no. 1: 6.
https://doi.org/10.3390/proceedings2020050006
APA Style
Stefanik, M., Ezebuo, F. C., Haviernik, J., Uzochukwu, I. C., Fojtikova, M., Salat, J., Eyer, L., & Ruzek, D.
(2020). FDA Approved Drugs Efavirenz, Tipranavir, and Dasabuvir Inhibit Replication of Multiple Flaviviruses In Vitro. Proceedings, 50(1), 6.
https://doi.org/10.3390/proceedings2020050006
